Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact

We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Maze Therapeutics, Inc. is one of the oversold stocks on our list.

TheFly reported on April 14 that Truist Securities maintained its Buy rating on MAZE while reducing its price target from $68 to $64. The revision follows the company’s recent 10-K report, with the firm adjusting its expense projections and updating share count estimates to account for pre-funded warrants currently outstanding.

Last month, on March 25, Maze Therapeutics, Inc. (NASDAQ:MAZE) released its fourth-quarter and full-year 2025 results, outlining financial performance and key clinical developments. The company reported cash, cash equivalents, and marketable securities of $360.0 million as of December 31, 2025, compared to $196.8 million a year earlier, with funding expected to support operations into 2028. Research and development expenses totaled $27.6 million for the quarter and $108.4 million for the year, while general and administrative costs reached $10.5 million and $34.5 million, respectively.

 Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact

The corporation also reported that its net loss was $34.6 million for the quarter and $131.1 million for the full year. Maze also shared positive Phase 2 data for MZE829, showing a 35.6% reduction in proteinuria at week 12, with stronger responses in certain subgroups. Additionally, the company advanced its pipeline, including plans for Phase 2 trials of MZE782 and progress on MZE001, supported by a $20 million milestone payment.

Maze Therapeutics, Inc. (NASDAQ:MAZE) is a clinical-stage biopharmaceutical company focused on developing small-molecule precision medicines for kidney and metabolic diseases. It uses human genetics and data-driven approaches to identify and target disease-causing biological pathways.

While we acknowledge the risk and potential of MAZE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MAZE and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest in According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.